Salsalate reverses metabolic disorders in a mouse model of non‐alcoholic fatty liver disease through AMPK activation and caspase‐6 activity inhibition-Reference-Cited by-同舟云学术

Salsalate reverses metabolic disorders in a mouse model of non‐alcoholic fatty liver disease through AMPK activation and caspase‐6 activity inhibition

Published:2020-11-27 Issue:3 Volume:128 Page:394-409
ISSN:1742-7835
Container-title:Basic & Clinical Pharmacology & Toxicology
language:en
Short-container-title:Basic Clin. Pharmacol. Toxicol.

Author:

Li Jingjing¹²,Chen Changmai³,Zhang Wei²,Bi Jing'ai²,Yang Guang⁴,Li Erguang¹²^ORCID

Affiliation:

1. State Key Laboratory of Pharmaceutical Biotechnology Medical School Nanjing University Nanjing China

2. Jiangsu Key Laboratory of Molecular Medicine Medical School Nanjing University Nanjing China

3. School of Pharmacy Fujian Medical University Fuzhou China

4. Nanjing Children’s HospitalNanjing Medical University Nanjing China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Pharmacology,Toxicology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcpt.13535

Reference78 articles.

1. Diabetes, Its Treatment, and Catastrophic Medical Spending in 35 Developing Countries

2. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB

3. IKK-β links inflammation to obesity-induced insulin resistance

4. The role of inflammation and macrophage accumulation in the development of obesity-induced type 2 diabetes mellitus and the possible therapeutic effects of long-chainn-3 PUFA

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Salicylate induces epithelial actin reorganization via activation of the AMP-activated protein kinase and promotes wound healing and contraction in mice;Scientific Reports;2024-07-16

2. NUAK1 promotes metabolic dysfunction-associated steatohepatitis progression by activating Caspase 6–driven pyroptosis and inflammation;Hepatology Communications;2024-07

3. Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis;Diabetes, Metabolic Syndrome and Obesity;2024-02

4. Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease;JHEP Reports;2024-02

5. Raspberry ketone ameliorates nonalcoholic fatty liver disease in rats by activating the AMPK pathway;European Journal of Pharmacology;2023-10